Basic characterization of 64Cu-ATSM as a radiotherapy agent
- 31 January 2005
- journal article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 32 (1), 21-28
- https://doi.org/10.1016/j.nucmedbio.2004.08.012
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Radioimmunotherapy for Acute LeukemiaCancer Control, 2002
- Combined modality radioimmunotherapyCancer, 2002
- Radioimmunotherapy of B-cell non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67Cu-2IT-BAT-Lym-1 RadioimmunotherapyCancer Biotherapy & Radiopharmaceuticals, 2001
- Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A ReviewCancer Biotherapy & Radiopharmaceuticals, 2000
- Trials and tribulations: Oncological antibody imaging comes to the foreSeminars in Nuclear Medicine, 1997
- Efficient production of high specific activity 64Cu using a biomedical cyclotronNuclear Medicine and Biology, 1997
- Concurrent Paclitaxel and Radiation Therapy for Solid TumorsCancer Control, 1996
- Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Similar Lethal Effect in Mammalian Cells for Two Radioisotopes of Copper with Different Decay Schemes,64Cu and67CuInternational Journal of Radiation Biology, 1989